Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.55 |
| ▸ | FNTB | P49356 | 5/20 | 0.55 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2700393 | 0.85 | MAOB (0.56) | FNTAFNTBPGGT1BRAB9AMAOB | |
| SCHEMBL18034623 | 0.85 | MAOB (0.47) | FNTAFNTBPGGT1BRAB9AMAOB | |
| Hydrochloric Acid SCHEMBL4488053 | 0.84 | MAOB (0.55) | FNTAFNTBPGGT1BRAB9AMAOB | |
| SCHEMBL8155625 | 0.81 | FNTA (0.60) | FNTAFNTBPGGT1BMAOBMAOA | |
| SCHEMBL22784142 | 0.81 | MAOB (0.54) | FNTAFNTBPGGT1BMAOBMAOA | |
| SCHEMBL6957296 | 0.81 | FNTA (0.52) | FNTAFNTBPGGT1BNPC1RAB9A | |
| SCHEMBL16943311 | 0.78 | KDM4E (0.49) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL361193 | 0.77 | ALDH1A1 (0.47) | FNTAFNTBPGGT1BKDM4EUSP2 | |
| SCHEMBL6431488 | 0.77 | KDM4E (0.56) | KDM4EUSP2ALDH1A1 | |
| SCHEMBL8807037 | 0.76 | MAOB (0.60) | RAB9AMAOBMAOAKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | disclosed |
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | FREYNE EDDY JEAN E (BE) | 2005-08-11 | — | — | US | disclosed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
| EP-1448556-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-25 | — | — | EP | disclosed |
| EP-1442019-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037869-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037891-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | GSK3B, GSK3A, PHKG1 | FNTA 3602/4885FNTB 884/4885PGGT1B 2160/4885 |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | GSK3B, GSK3A, GSKIP | FNTA 2355/4885FNTB 789/4885PGGT1B 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.